Dr. Gandara on the MYSTIC Trial for Lung Cancer

David R. Gandara, MD
Published: Friday, Aug 25, 2017



David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC).

The results of the MYSTIC trial have been much anticipated, explains Gandara. This is a phase III trial in advanced-stage NSCLC, randomizing patients to standard-of-care platinum chemotherapy versus either durvalumab (Imfinzi) alone or durvalumab plus tremelimumab, a CTLA-4 inhibitor.

In a press release from AstraZeneca, it was reported that the primary endpoint of progression-free survival was not met in either of the experimental arms. No data have been reported in terms of the magnitude of benefit; it was just reported that the primary endpoint was not met, states Gandara.



David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC).

The results of the MYSTIC trial have been much anticipated, explains Gandara. This is a phase III trial in advanced-stage NSCLC, randomizing patients to standard-of-care platinum chemotherapy versus either durvalumab (Imfinzi) alone or durvalumab plus tremelimumab, a CTLA-4 inhibitor.

In a press release from AstraZeneca, it was reported that the primary endpoint of progression-free survival was not met in either of the experimental arms. No data have been reported in terms of the magnitude of benefit; it was just reported that the primary endpoint was not met, states Gandara.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x